{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T06:13:35Z","timestamp":1792476815775,"version":"4.5.0"},"reference-count":85,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:00:00Z","timestamp":1736208000000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016036","name":"Health~Holland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016036","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020068","name":"Topconsortium voor Kennis en Innovatie","doi-asserted-by":"publisher","award":["LSHM22041"],"award-info":[{"award-number":["LSHM22041"]}],"id":[{"id":"10.13039\/501100020068","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.pnpbp.2025.111251","type":"journal-article","created":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T03:08:33Z","timestamp":1736219313000},"page":"111251","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Neurobiological mechanisms of antidepressant properties of psilocybin: A systematic review of blood biomarkers"],"prefix":"10.1016","volume":"136","author":[{"given":"Juliana Lima","family":"Constantino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens H.","family":"van Dalfsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Massetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanine","family":"Kamphuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Schoevers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.pnpbp.2025.111251_bb0005","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.tips.2021.08.003","article-title":"Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics","volume":"42","author":"Aleksandrova","year":"2021","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.pnpbp.2025.111251_bb0010","article-title":"Cause or consequence? Understanding the role of cortisol in the increased inflammation observed in depression","volume":"24","author":"Amasi-Hartoonian","year":"2022","journal-title":"Curr. Opin. Endocr. Metab. Res."},{"issue":"14","key":"10.1016\/j.pnpbp.2025.111251_bb0015","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/0024-3205(87)90600-X","article-title":"Oxytocin acts as an antidepressant in two animal models of depression","volume":"41","author":"Arletti","year":"1987","journal-title":"Life Sci."},{"issue":"11","key":"10.1016\/j.pnpbp.2025.111251_bb0020","article-title":"A comprehensive review of the current status of the cellular neurobiology of psychedelics","volume":"12","author":"Banushi","year":"2023","journal-title":"Biology (Basel)"},{"issue":"12","key":"10.1016\/j.pnpbp.2025.111251_bb0025","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1177\/0269881116678781","article-title":"The challenging experience questionnaire: characterization of challenging experiences with psilocybin mushrooms","volume":"30","author":"Barrett","year":"2016","journal-title":"J. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.pnpbp.2025.111251_bb0030","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/cpt.2487","article-title":"Acute effects of psilocybin after escitalopram or placebo pretreatment in a randomized, double-blind, placebo-controlled, crossover study in healthy subjects","volume":"111","author":"Becker","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.pnpbp.2025.111251_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpnec.2022.100163","article-title":"Subacute effects of a single dose of psilocybin on biomarkers of inflammation in healthy humans: an open-label preliminary investigation","volume":"13","author":"Burmester","year":"2023","journal-title":"Compr. Psychoneuroendocrinol."},{"issue":"15","key":"10.1016\/j.pnpbp.2025.111251_bb0040","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","article-title":"Trial of psilocybin versus escitalopram for depression","volume":"384","author":"Carhart-Harris","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.pnpbp.2025.111251_bb0045","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.cell.2021.01.034","article-title":"Antidepressant drugs act by directly binding to TRKB neurotrophin receptors","volume":"184","author":"Casarotto","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.pnpbp.2025.111251_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2023.105159","article-title":"The role of BDNF in major depressive disorder, related clinical features, and antidepressant treatment: insight from meta-analyses","volume":"149","author":"Cavaleri","year":"2023","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.pnpbp.2025.111251_bb0055","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.euroneuro.2020.01.011","article-title":"The impact of selective serotonin reuptake inhibitors on the thyroid function among patients with major depressive disorder: a systematic review and meta-analysis","volume":"33","author":"Caye","year":"2020","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"5","key":"10.1016\/j.pnpbp.2025.111251_bb0060","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1017\/S1461145707008206","article-title":"Efficacy and safety of triiodothyronine supplementation in patients with major depressive disorder treated with specific serotonin reuptake inhibitors","volume":"11","author":"Cooper-Kazaz","year":"2008","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111251_bb0065","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1743-6109.2006.00394.x","article-title":"Oxytocin involvement in SSRI-induced delayed ejaculation: a review of animal studies","volume":"4","author":"de Jong","year":"2007","journal-title":"J. Sex. Med."},{"issue":"2","key":"10.1016\/j.pnpbp.2025.111251_bb0070","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/14737175.2016.1220834","article-title":"Psilocybin for treating substance use disorders?","volume":"17","author":"de Veen","year":"2017","journal-title":"Expert. Rev. Neurother."},{"key":"10.1016\/j.pnpbp.2025.111251_bb0075","article-title":"Psychedelics and neuroplasticity: a systematic review unraveling the biological underpinnings of psychedelics","volume":"12","author":"de Vos","year":"2021","journal-title":"Front. Psychol."},{"issue":"2","key":"10.1016\/j.pnpbp.2025.111251_bb0080","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S2215-0366(21)00395-3","article-title":"Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990-2019: a systematic analysis for the global burden of disease study 2019","volume":"9","author":"Diseases","year":"2022","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.pnpbp.2025.111251_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpnec.2021.100049","article-title":"Plasma prolactin is higher in major depressive disorder and females, and associated with anxiety, hostility, somatization, psychotic symptoms and heart rate","volume":"6","author":"Elgellaie","year":"2021","journal-title":"Compr. Psychoneuroendocrinol."},{"key":"10.1016\/j.pnpbp.2025.111251_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2022.104758","article-title":"Insulin resistance in depression: a large meta-analysis of metabolic parameters and variation","volume":"139","author":"Fernandes","year":"2022","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.pnpbp.2025.111251_bb0095","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.psyneuen.2018.11.035","article-title":"Associations between symptoms of depression and anxiety and cortisol responses to and recovery from acute stress","volume":"102","author":"Fiksdal","year":"2019","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.pnpbp.2025.111251_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.psyneuen.2019.104438","article-title":"Effects of acute psychosocial stress on the hypothalamic-pituitary-thyroid (HPT) axis in healthy women","volume":"110","author":"Fischer","year":"2019","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.pnpbp.2025.111251_bb0105","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/7854_2022_367","article-title":"Psychedelics and anti-inflammatory activity in animal models","volume":"56","author":"Flanagan","year":"2022","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"10.1016\/j.pnpbp.2025.111251_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2021.114317","article-title":"Fluoxetine modulates the pro-inflammatory process of IL-6, IL-1\u03b2 and TNF-\u03b1 levels in individuals with depression: a systematic review and meta-analysis","volume":"307","author":"Garc\u00eda-Garc\u00eda","year":"2022","journal-title":"Psychiatry Res."},{"issue":"2","key":"10.1016\/j.pnpbp.2025.111251_bb0115","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/da.22968","article-title":"Defining treatment-resistant depression","volume":"37","author":"Gaynes","year":"2020","journal-title":"Depress. Anxiety"},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111251_bb0120","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/mp.2014.163","article-title":"The organization of the stress system and its dysregulation in depressive illness","volume":"20","author":"Gold","year":"2015","journal-title":"Mol. Psychiatry"},{"issue":"18","key":"10.1016\/j.pnpbp.2025.111251_bb0125","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","article-title":"Single-dose psilocybin for a treatment-resistant episode of major depression","volume":"387","author":"Goodwin","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111251_bb0130","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s002130050860","article-title":"Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers. Results of an experimental double-blind placebo-controlled study","volume":"142","author":"Gouzoulis-Mayfrank","year":"1999","journal-title":"Psychopharmacology"},{"issue":"1\u20133","key":"10.1016\/j.pnpbp.2025.111251_bb0135","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jad.2012.11.008","article-title":"Recurrence of major depressive disorder across different treatment settings: results from the NESDA study","volume":"147","author":"Hardeveld","year":"2013","journal-title":"J. Affect. Disord."},{"issue":"2","key":"10.1016\/j.pnpbp.2025.111251_bb0140","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00213-003-1640-6","article-title":"Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study","volume":"172","author":"Hasler","year":"2004","journal-title":"Psychopharmacology"},{"issue":"17","key":"10.1016\/j.pnpbp.2025.111251_bb0145","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2022489118","article-title":"Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice","volume":"118","author":"Hesselgrave","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.pnpbp.2025.111251_bb0150","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0010-440X(62)80024-8","article-title":"Mescaline, lysergic acid diethylamide and psilocybin comparison of clinical syndromes, effects on color perception and biochemical measures","volume":"3","author":"Hollister","year":"1962","journal-title":"Compr. Psychiatry"},{"key":"10.1016\/j.pnpbp.2025.111251_bb0155","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/S0010-440X(64)80030-4","article-title":"Clinical syndromes and biochemical alterations following mescaline, lysergic acid diethylamide, psilocybin and a combination of the three psychotomimetic drugs","volume":"5","author":"Hollister","year":"1964","journal-title":"Compr. Psychiatry"},{"issue":"6","key":"10.1016\/j.pnpbp.2025.111251_bb0160","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/s41386-022-01297-2","article-title":"Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects","volume":"47","author":"Holze","year":"2022","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2025.111251_bb0165","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.euroneuro.2020.11.001","article-title":"Towards precision medicine: what are the stratification hypotheses to identify homogeneous inflammatory subgroups","volume":"45","author":"Ioannou","year":"2021","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.pnpbp.2025.111251_bb0170","doi-asserted-by":"crossref","first-page":"1085950","DOI":"10.3389\/fendo.2023.1085950","article-title":"Understanding the relationships between physiological and psychosocial stress, cortisol and cognition","volume":"14","author":"James","year":"2023","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"3","key":"10.1016\/j.pnpbp.2025.111251_bb0175","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2217\/bmm.14.114","article-title":"Biomarker approaches in major depressive disorder evaluated in the context of current hypotheses","volume":"9","author":"Jentsch","year":"2015","journal-title":"Biomark. Med"},{"issue":"8","key":"10.1016\/j.pnpbp.2025.111251_bb0180","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1021\/acsptsci.3c00123","article-title":"Transient elevation of plasma glucocorticoids supports psilocybin-induced Anxiolysis in mice","volume":"6","author":"Jones","year":"2023","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.pnpbp.2025.111251_bb0185","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jad.2017.09.052","article-title":"Atypical depression and non-atypical depression: is HPA axis function a biomarker? A systematic review","volume":"233","author":"Juruena","year":"2018","journal-title":"J. Affect. Disord."},{"issue":"2","key":"10.1016\/j.pnpbp.2025.111251_bb0190","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41380-019-0585-z","article-title":"Prospective biomarkers of major depressive disorder: a systematic review and meta-analysis","volume":"25","author":"Kennis","year":"2020","journal-title":"Mol. Psychiatry"},{"issue":"6","key":"10.1016\/j.pnpbp.2025.111251_bb0195","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1001\/archpsyc.62.6.617","article-title":"Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication","volume":"62","author":"Kessler","year":"2005","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.pnpbp.2025.111251_bb0200","article-title":"In silico studies on psilocybin drug derivatives against SARS-CoV-2 and cytokine storm of human Interleukin-6 receptor","volume":"12","author":"Khan","year":"2021","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111251_bb0205","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/s41386-023-01717-x","article-title":"The role of neurotrophic factors in novel, rapid psychiatric treatments","volume":"49","author":"Kim","year":"2024","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"10.1016\/j.pnpbp.2025.111251_bb0210","first-page":"4195","article-title":"Peripheral alterations in cytokine and chemokine levels after antidepressant drug treatment for major depressive disorder: systematic review and Meta-analysis","volume":"55","author":"K\u00f6hler","year":"2018","journal-title":"Mol. Neurobiol."},{"issue":"6","key":"10.1016\/j.pnpbp.2025.111251_bb0215","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1159\/000350094","article-title":"Molecular mechanisms of depression: perspectives on new treatment strategies","volume":"31","author":"Lang","year":"2013","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.pnpbp.2025.111251_bb0220","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.3389\/fimmu.2019.01696","article-title":"The role of inflammation in depression and fatigue","volume":"10","author":"Lee","year":"2019","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.pnpbp.2025.111251_bb0225","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1038\/s41386-023-01607-2","article-title":"Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants","volume":"48","author":"Ley","year":"2023","journal-title":"Neuropsychopharmacology"},{"issue":"10","key":"10.1016\/j.pnpbp.2025.111251_bb0230","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1038\/s41386-019-0391-y","article-title":"Acute psychosocial stress increases serum BDNF levels: an antagonistic relation to cortisol but no group differences after mental training","volume":"44","author":"Linz","year":"2019","journal-title":"Neuropsychopharmacology"},{"issue":"7","key":"10.1016\/j.pnpbp.2025.111251_bb0235","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1038\/s41380-020-00867-4","article-title":"The longitudinal associations of inflammatory biomarkers and depression revisited: systematic review, meta-analysis, and meta-regression","volume":"26","author":"Mac Giollabhui","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2025.111251_bb0240","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.bbi.2017.01.011","article-title":"The effects of acute psychological stress on circulating and stimulated inflammatory markers: a systematic review and meta-analysis","volume":"64","author":"Marsland","year":"2017","journal-title":"Brain Behav. Immun."},{"issue":"12","key":"10.1016\/j.pnpbp.2025.111251_bb0245","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1038\/s41386-020-0718-8","article-title":"Me, myself, bye: regional alterations in glutamate and the experience of ego dissolution with psilocybin","volume":"45","author":"Mason","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2025.111251_bb0250","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.bbi.2023.09.004","article-title":"Psilocybin induces acute and persisting alterations in immune status in healthy volunteers: an experimental, placebo-controlled study","volume":"114","author":"Mason","year":"2023","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.pnpbp.2025.111251_bb0255","article-title":"Growth hormone, inflammation and aging","volume":"2","author":"Masternak","year":"2012","journal-title":"Pathobiol. Aging Age Relat. Dis."},{"key":"10.1016\/j.pnpbp.2025.111251_bb0260","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.neubiorev.2014.07.005","article-title":"Making room for oxytocin in understanding depression","volume":"45","author":"McQuaid","year":"2014","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"9","key":"10.1016\/j.pnpbp.2025.111251_bb0265","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1038\/s41380-022-01652-1","article-title":"Blood-based biomarkers of antidepressant response to ketamine and esketamine: a systematic review and meta-analysis","volume":"27","author":"Medeiros","year":"2022","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2025.111251_bb0270","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jad.2022.12.021","article-title":"Biomarkers of ketamine\u2019s antidepressant effect: an umbrella review","volume":"323","author":"Meshkat","year":"2023","journal-title":"J. Affect. Disord."},{"issue":"6","key":"10.1016\/j.pnpbp.2025.111251_bb0275","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1017\/S0033291709991036","article-title":"How common are common mental disorders? Evidence that lifetime prevalence rates are doubled by prospective versus retrospective ascertainment","volume":"40","author":"Moffitt","year":"2010","journal-title":"Psychol. Med."},{"issue":"6","key":"10.1016\/j.pnpbp.2025.111251_bb0280","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/s41593-023-01316-5","article-title":"Psychedelics promote plasticity by directly binding to BDNF receptor TrkB","volume":"26","author":"Moliner","year":"2023","journal-title":"Nat. Neurosci."},{"issue":"8","key":"10.1016\/j.pnpbp.2025.111251_bb0285","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10081706","article-title":"Effects of antidepressant treatment on peripheral biomarkers in patients with major depressive disorder (MDD)","volume":"10","author":"Mosio\u0142ek","year":"2021","journal-title":"J. Clin. Med."},{"issue":"9590","key":"10.1016\/j.pnpbp.2025.111251_bb0290","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S0140-6736(07)61415-9","article-title":"Depression, chronic diseases, and decrements in health: results from the world health surveys","volume":"370","author":"Moussavi","year":"2007","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.pnpbp.2025.111251_bb0295","article-title":"Phytochemical, cytotoxicity, antioxidant and anti-inflammatory effects of Psilocybe Natalensis magic mushroom","volume":"9","author":"Nkadimeng","year":"2020","journal-title":"Plants (Basel)"},{"key":"10.1016\/j.pnpbp.2025.111251_bb0300","doi-asserted-by":"crossref","first-page":"3729","DOI":"10.2147\/JIR.S317182","article-title":"Anti-inflammatory effects of four psilocybin-containing magic mushroom water extracts in vitro on 15-lipoxygenase activity and on lipopolysaccharide-induced Cyclooxygenase-2 and inflammatory cytokines in human U937 macrophage cells","volume":"14","author":"Nkadimeng","year":"2021","journal-title":"J. Inflamm. Res."},{"key":"10.1016\/j.pnpbp.2025.111251_bb0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.comppsych.2019.152143","article-title":"Longitudinal population subgroups of CRP and risk of depression in the ALSPAC birth cohort","volume":"96","author":"Osimo","year":"2020","journal-title":"Compr. Psychiatry"},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111251_bb0310","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst. Rev."},{"key":"10.1016\/j.pnpbp.2025.111251_bb0315","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Bmj"},{"issue":"6","key":"10.1016\/j.pnpbp.2025.111251_bb0320","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.euroneuro.2017.04.001","article-title":"Why are depressed patients inflamed? A reflection on 20 years of research on depression, glucocorticoid resistance and inflammation","volume":"27","author":"Pariante","year":"2017","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"3","key":"10.1016\/j.pnpbp.2025.111251_bb0325","doi-asserted-by":"crossref","first-page":"368","DOI":"10.4306\/pi.2017.14.3.368","article-title":"Serum prolactin levels in patients with major depressive disorder receiving selective serotonin-reuptake inhibitor monotherapy for 3 months: a prospective study","volume":"14","author":"Park","year":"2017","journal-title":"Psychiatry Investig."},{"issue":"5","key":"10.1016\/j.pnpbp.2025.111251_bb0330","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1159\/000318293","article-title":"Efficacy and effectiveness of antidepressants: current status of research","volume":"79","author":"Pigott","year":"2010","journal-title":"Psychother. Psychosom."},{"issue":"7","key":"10.1016\/j.pnpbp.2025.111251_bb0335","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-063095","volume":"13","author":"Pigott","year":"2023","journal-title":"BMJ Open"},{"issue":"9","key":"10.1016\/j.pnpbp.2025.111251_bb0340","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/jama.2023.14530","article-title":"Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial","volume":"330","author":"Raison","year":"2023","journal-title":"Jama"},{"issue":"11","key":"10.1016\/j.pnpbp.2025.111251_bb0345","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report","volume":"163","author":"Rush","year":"2006","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111251_bb0350","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1248\/bpb.b14-00315","article-title":"Effect of psilocin on extracellular dopamine and serotonin levels in the mesoaccumbens and mesocortical pathway in awake rats","volume":"38","author":"Sakashita","year":"2015","journal-title":"Biol. Pharm. Bull."},{"issue":"4","key":"10.1016\/j.pnpbp.2025.111251_bb0355","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.psyneuen.2007.01.009","article-title":"Plasma oxytocin levels and anxiety in patients with major depression","volume":"32","author":"Scantamburlo","year":"2007","journal-title":"Psychoneuroendocrinology"},{"issue":"4","key":"10.1016\/j.pnpbp.2025.111251_bb0360","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0893-133X(95)00117-V","article-title":"Neuroendocrine effects of a 20-mg citalopram infusion in healthy males. A placebo-controlled evaluation of citalopram as 5-HT function probe","volume":"14","author":"Seifritz","year":"1996","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2025.111251_bb0365","doi-asserted-by":"crossref","DOI":"10.1038\/s41386-024-01794-6","article-title":"Antidepressant-like effects of psychedelics in a chronic despair mouse model: is the 5-HT(2A) receptor the unique player?","author":"Sekssaoui","year":"2024","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/j.pnpbp.2025.111251_bb0370","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/s44220-023-00016-0","article-title":"The interplay of acute cortisol response and trait affectivity in associating with stress resilience","volume":"1","author":"Shao","year":"2023","journal-title":"Nat. Ment. Health"},{"issue":"7","key":"10.1016\/j.pnpbp.2025.111251_bb0375","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1177\/02698811221092508","article-title":"Neural mechanisms underlying psilocybin\u2019s therapeutic potential - the need for preclinical in vivo electrophysiology","volume":"36","author":"Smausz","year":"2022","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2025.111251_bb0380","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3389\/fendo.2016.00025","article-title":"Actions of prolactin in the brain: from physiological adaptations to stress and neurogenesis to psychopathology","volume":"7","author":"Torner","year":"2016","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111251_bb0385","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s002130050867","article-title":"Oxytocin as a possible mediator of SSRI-induced antidepressant effects","volume":"142","author":"Uvn\u00e4s-Moberg","year":"1999","journal-title":"Psychopharmacology"},{"issue":"8","key":"10.1016\/j.pnpbp.2025.111251_bb0390","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1523\/JNEUROSCI.17-08-02785.1997","article-title":"5-HT2A receptor-mediated regulation of brain-derived neurotrophic factor mRNA in the hippocampus and the neocortex","volume":"17","author":"Vaidya","year":"1997","journal-title":"J. Neurosci."},{"issue":"1","key":"10.1016\/j.pnpbp.2025.111251_bb0395","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.17m11475","article-title":"Validity of the Maudsley staging method in predicting treatment-resistant depression outcome using the Netherlands study of depression and anxiety","volume":"79","author":"van Belkum","year":"2018","journal-title":"J. Clin. Psychiatry"},{"issue":"18","key":"10.1016\/j.pnpbp.2025.111251_bb0400","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1007\/s40265-017-0819-9","article-title":"Progress in elucidating biomarkers of antidepressant pharmacological treatment response: a systematic review and Meta-analysis of the last 15 years","volume":"77","author":"Voegeli","year":"2017","journal-title":"Drugs"},{"issue":"17","key":"10.1016\/j.pnpbp.2025.111251_bb0405","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1097\/00001756-199812010-00024","article-title":"Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action","volume":"9","author":"Vollenweider","year":"1998","journal-title":"NeuroReport"},{"key":"10.1016\/j.pnpbp.2025.111251_bb0410","article-title":"Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial","volume":"56","author":"von Rotz","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"Pt C","key":"10.1016\/j.pnpbp.2025.111251_bb0415","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.pnpbp.2017.04.026","article-title":"Effect of antidepressant treatment on peripheral inflammation markers - a meta-analysis","volume":"80","author":"Wi\u0119d\u0142ocha","year":"2018","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"6","key":"10.1016\/j.pnpbp.2025.111251_bb0420","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1007\/s43440-023-00539-4","article-title":"Cardiovascular safety of psychedelic medicine: current status and future directions","volume":"75","author":"Ws\u00f3\u0142","year":"2023","journal-title":"Pharmacol. Rep."},{"issue":"6","key":"10.1016\/j.pnpbp.2025.111251_bb0425","doi-asserted-by":"crossref","DOI":"10.3390\/molecules28062624","article-title":"The effect of combined treatment of psilocybin and eugenol on lipopolysaccharide-induced brain inflammation in mice","volume":"28","author":"Zanikov","year":"2023","journal-title":"Molecules"}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584625000053?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584625000053?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T19:24:07Z","timestamp":1762284247000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584625000053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":85,"alternative-id":["S0278584625000053"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2025.111251","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neurobiological mechanisms of antidepressant properties of psilocybin: A systematic review of blood biomarkers","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2025.111251","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"111251"}}